Of particular importance, HER2-positivebreast cancer represents a significant fraction of breast cancers,with a prevalence of approximately 20–30%.3,4 Precisediagnosis of HER2 is crucial in selecting effective regimens for individualizedtreatment, given the rapid development of precision medicine. This evidence concerns the gene ERBB2 and cancer.